What does the company do?
Cell Therapeutics, Inc. (Cell Therapeutics) develops, acquires and commercializes treatments for cancer. The Company’s research, development, acquisition and in-licensing activities concentrate on identifying and developing new, less toxic and effective ways to treat cancer. Cell Therapeutics is developing pixantrone (BBR 2778), a deoxyribonucleic acid (DNA) major groove binder with an aza-anthracenedione molecular structure, differentiating it from anthracycline chemotherapy agents. A new chemical compound for the treatment of non-Hodgkin’s lymphoma (NHL), and various other hematologic malignancies, solid tumors, and immunological disorders, pixantrone is being developed to improve activity and safety in treating cancers treated with the anthracycline family of anti-cancer agents. It is developing OPAXIO (paclitaxel poliglumex), which was previously referred to as XYOTAX, for the treatment of non-small cell lung cancer (NSCLC), and ovarian cancer.
How much does the company sell and earn?
Investors need to know how much stuff or services a company sells, and how much of that total it keeps as income (or profit) to grow its business or return to shareholders. The more of each, the better. In general, look for companies that sell and earn more than peers.
- Cell Thera one-year sales: 2.61 Mil.
Difference from the average for the Biotechnology group: -99.95% - Cell Thera one-year income: -130.73 Mil.
| Sales & Income (past 12 months) | Company | Industry |
|---|
| Sales | 2.61 Mil | 5.77 Bil | | Income | -130.73 Mil | 1.61 Bil |
How fast is the company growing?
- Cell Thera one-year sales growth: -99.30%.
| Sales & Income Growth (past 12 months) | Company | Industry |
|---|
| Sales Growth | -99.30% | 26.20% | | Income Growth | NA | 28.00% |
How profitable is the company?
Investors prefer companies that increase profit margins -- the percentage of sales that they keep -- every year. This is accomplished either by lowering expenses or raising prices. Look for companies that consistently find ways to squeeze more profits out of sales than their peers.
How is the company's financial health?
The debt/equity ratio shows how much a firm has borrowed as a percentage of its stock equity. The lower, the better.
Data not available for this company.
|
Recent News